BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

The partnership brings together BoomRay’s development experience in RLTs and Novartis’s global presence in the field. Credit: Michael Derrer Fuchs / Shutterstock.com.



  • BoomRay Pharmaceuticals Novartis